{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:58:56Z","timestamp":1761764336380},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Vardenafil (Levitra\u00ae) is a potent and selective phosphodiesterase 5 (PDE5) inhibitor used in the management of erectile dysfunction (ED). This retrospective subgroup analysis assessed the effectiveness of vardenafil treatment in men with ED of different baseline severity and disease classification.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from two pivotal, randomized, double-blind, placebo-controlled clinical trials enrolling men from the general ED population who received placebo or vardenafil 5 mg, 10 mg, or 20 mg during a 12-week treatment period were retrospectively analysed, stratifying by psychogenic, organic, and mixed ED disease classification as determined by the investigator. Efficacy endpoints included the International Index of Erectile Function (IIEF)-Erectile Function (EF) domain score, per-patient diary response rates to questions on penile insertion [Sexual Encounter Profile (SEP-2)] and maintenance of erection (SEP-3) and rates of positive response to the Global Assessment Question (GAQ).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 1,385 men who received at least one dose of study medication and had pre- and post-baseline measures of efficacy available (intent-to-treat population) are presented. At baseline 37\u201341% of patients had severe ED, 30\u201334% moderate, 22% mild-to-moderate and 6\u20138% mild ED. At baseline, 46\u201351% of patients were considered to have an organic cause for ED, 13\u201316% psychogenic ED, and 36\u201338% mixed classification of ED. For all classifications and for mild-to-moderate to severe ED, men treated with 10 or 20 mg of vardenafil showed statistically and clinically \u200asignificant \u200aimprovements \u200a(P &amp;lt; 0.001) \u200ain \u200aIIEF-EF \u200ascores, \u200adiary \u200aresponse \u200arates \u200ato \u200athe SEP-2 and SEP-3 questions, and GAQ as compared with those given placebo. The greatest improvements relative to placebo were noted in patients with more severe ED. The most common treatment-emergent adverse events were headache, flushing, rhinitis, dyspepsia, and were dose-related, mostly mild to moderate in intensity and consistent with the class.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Vardenafil improves EF in men with ED irrespective of investigator-determined classification and baseline ED severity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.04043.x","type":"journal-article","created":{"date-parts":[[2004,10,13]],"date-time":"2004-10-13T14:00:40Z","timestamp":1097676040000},"page":"301-309","source":"Crossref","is-referenced-by-count":29,"title":["Vardenafil Improves Erectile Function in Men with Erectile Dysfunction Irrespective of Disease Severity and Disease Classification"],"prefix":"10.1093","volume":"1","author":[{"given":"Craig","family":"Donatucci","sequence":"first","affiliation":[{"name":"Duke University Medical Center , Durham , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Eardley","sequence":"additional","affiliation":[{"name":"St. James University Hospital , Leeds , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Buvat","sequence":"additional","affiliation":[{"name":"Centre ETPARP , Lille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Gittelman","sequence":"additional","affiliation":[{"name":"South Florida Medical Research , Aventura, FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Kell","sequence":"additional","affiliation":[{"name":"Hospital of St John and St Elizabeth , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thom","family":"Segerson","sequence":"additional","affiliation":[{"name":"Bayer Inc., Toronto , Ontario , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Homering","sequence":"additional","affiliation":[{"name":"BayerHealthCare AG , Wuppertal , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[{"name":"Divisione di Urologia, Instituto San Raffaele , Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,11,1]]},"reference":[{"key":"2024032600074948500_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH consensus development panel on impotence","volume":"270","author":"NIH Consensus Conference.","year":"1993","journal-title":"JAMA"},{"key":"2024032600074948500_bib2","first-page":"147","article-title":"NIH releases consensus statement on impotence","volume":"48","year":"1993","journal-title":"Am Fam Physician"},{"key":"2024032600074948500_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(00)00655-0","article-title":"Diagnosis and treatment of erectile dysfunction","volume":"109","author":"Levine","year":"2000","journal-title":"Am J Med"},{"key":"2024032600074948500_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1365-2265.2000.00954.x","article-title":"Non-surgical management of erectile dysfunction","volume":"52","author":"Levy","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024032600074948500_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0090-4295(99)80304-5","article-title":"A brief male sexual function inventory for urology","volume":"46","author":"O'Leary","year":"1995","journal-title":"Urology"},{"key":"2024032600074948500_bib6","first-page":"711","article-title":"Recommendations of the 1st International consultation on erectile dysfunction","author":"Jardin","year":"2000:","journal-title":"Erectile dysfunction"},{"key":"2024032600074948500_bib7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0090-4295(99)00099-0","article-title":"Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function","volume":"54","author":"Cappelleri","year":"1999","journal-title":"Urology"},{"key":"2024032600074948500_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","article-title":"Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction","volume":"11","author":"Rosen","year":"1999","journal-title":"Int J Impot Res"},{"key":"2024032600074948500_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.26.3.777","article-title":"Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study","volume":"26","author":"Goldstein","year":"2003","journal-title":"Diabetes Care"},{"key":"2024032600074948500_bib10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1097\/01.ju.0000086947.00547.49","article-title":"Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy","volume":"170","author":"Brock","year":"2003","journal-title":"J Urol"},{"issue":"5 suppl","key":"2024032600074948500_bib11","first-page":"S","article-title":"Vardenafil exhibits efficacy in men with erectile dysfunction unresponsive to prior sildenafil therapy: Results of a phase III clinical trial\u2014Patient Response with Vardenafil in Sildenafil Nonresponders (PROVEN)","volume":"15","author":"Carson","year":"2003","journal-title":"Int J Impot Res"},{"key":"2024032600074948500_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0090-4295(03)00491-6","article-title":"Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups","volume":"62","author":"Porst","year":"2003","journal-title":"Urology"},{"key":"2024032600074948500_bib13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1939-4640.2002.tb02323.x","article-title":"Challenges in oral therapy for erectile dysfunction","volume":"23","author":"Seftel","year":"2002","journal-title":"J Androl"},{"key":"2024032600074948500_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ijir.3900420","article-title":"Interdisciplinary assessment and follow-up of patients with erectile dysfunction\u2014psychiatric aspects","volume":"11","author":"Caspari","year":"1999","journal-title":"Int J Impot Res"},{"key":"2024032600074948500_bib15","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0090-4295(98)00643-8","article-title":"Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies","volume":"53","author":"Montorsi","year":"1999","journal-title":"Urology"},{"key":"2024032600074948500_bib16","first-page":"177","article-title":"Vardenafil restores normal functioning to men with erectile dysfunction","volume":"167","author":"Padma-Nathan","year":"2002","journal-title":"J Urol"},{"key":"2024032600074948500_bib17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1742-1241.2003.tb10567.x","article-title":"The potential value of erectile dysfunction inquiry and management","volume":"57","author":"Sadovsky","year":"2003","journal-title":"Int J Clin Pract"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515310778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515310778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/1\/3\/301\/47522447\/jsm_1_3_301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/1\/3\/301\/47522447\/jsm_1_3_301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:05:18Z","timestamp":1711415118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/1\/3\/301\/6863030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,1]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2004,11,1]]},"published-print":{"date-parts":[[2004,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.04043.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2004,11]]},"published":{"date-parts":[[2004,11,1]]}}}